Publications by authors named "W N Rosenfeld"
Article Synopsis
- Cenobamate has proven effective for patients with treatment-resistant epilepsy, including those who still experience seizures post-surgery, leading experts to recommend its use during the surgical evaluation process.
- A panel of six epilepsy specialists suggests that both cenobamate and antiseizure medication (ASM) should be personalized and optimized during presurgical evaluations, with cenobamate potentially helping many patients achieve seizure freedom.
- While cenobamate can be initiated before surgery, especially for patients not ideal for surgery, it should not delay necessary operations, and patients may choose to forgo surgery if they attain lasting seizure control with cenobamate.
Background: Cenobamate is an antiseizure medication (ASM) approved in the US and Europe for the treatment of uncontrolled focal seizures.
Objective: This post hoc analysis of a phase III, open-label safety study assessed the safety and efficacy of adjunctive cenobamate in older adults versus the overall study population.
Methods: Adults aged 18-70 years with uncontrolled focal seizures taking stable doses of one to three ASMs were enrolled in the phase III, open-label safety study; adults aged 65-70 years from that study were included in our safety analysis.
Objective: Many patients with epilepsy require polytherapy, which increases their antiseizure medication (ASM) drug load, a measure that considers the doses of all ASMs a patient is taking. Changes in concomitant ASM drug load after adding cenobamate were evaluated post-hoc in a subset of the open-label, phase 3 study.
Methods: Patients 18-70 years old with uncontrolled focal seizures taking 1-3 ASMs were enrolled.
Objective: Cognitive and psychiatric adverse events in patients with epilepsy are important determinants of therapeutic outcomes and patient quality of life. We assessed the relationship between adjunctive cenobamate treatment and selected cognitive and psychiatric treatment-emergent adverse events (TEAEs) in adults with uncontrolled focal epilepsy.
Methods: This was a retrospective analysis of pooled populations of patients with focal epilepsy from two phase 2, randomized, double-blind clinical trials; two open-label extensions (OLEs) of those trials; and a long-term, open-label, phase 3 safety study.